OBLN - Obalon Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.7499
+0.0539 (+7.74%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.6960
Open0.7227
Bid0.7310 x 1000
Ask0.7451 x 3100
Day's Range0.7000 - 0.8598
52 Week Range0.6200 - 10.5000
Volume2,412,675
Avg. Volume706,515
Market Cap5.798M
Beta (5Y Monthly)-1.14
PE Ratio (TTM)N/A
EPS (TTM)-3.4070
Earnings DateJun. 19, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
  • GlobeNewswire

    Obalon Announces First Quarter 2020 Financial Results and Business Update

    SAN DIEGO, June 19, 2020 -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment

    Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California as a result of Covid-19 have had a significant impact on Obalon’s business. In March, the Company halted sales to new patients in its company-branded retail treatment centers and expansion plans for additional retail centers, which was particularly disappointing as it had generated an average of approximately 30 new patient sales per month at its San Diego center for the three months preceding the Covid-19 crisis.

  • GlobeNewswire

    William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that William Plovanic, the Company’s President and CEO has announced his resignation in order to accept another position. To assist the Company in the transition, Mr. Plovanic has agreed to remain as President and CEO through completion and filing of Obalon’s Form 10-Q for the quarter ended March 31, 2020 (the “Quarterly Report”).

  • GlobeNewswire

    Obalon Gas-Filled Balloon Not Subject of Fourth FDA Letter to Health Care Providers Related To Serious Risks, Including Death, With Liquid-Filled Intragastric Balloons

    Obalon Therapeutics, Inc. (OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity provided further clarification that it’s gas-filled balloon is not the subject of the April 27, 2020 letter issued by the FDA to health care providers warning of serious potential risks, including deaths, associated with the use of liquid-filled intragastric balloons. The Obalon swallowable, gas-filled balloon system utilizes a very different design and technology than the liquid-filled balloons cited now in four FDA letters to health care providers.

  • GlobeNewswire

    Obalon Engages Canaccord Genuity to Explore Financial and Strategic Alternatives

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that its Board of Directors has decided to explore potential financial and strategic alternatives intended to enhance stockholder value. The Company has engaged Canaccord Genuity LLC as its financial advisor. The overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California regarding Covid-19 has had an immediate impact on Obalon’s business.

  • GlobeNewswire

    Obalon Temporarily Suspends New Patient Sales at Its Retail Treatment Centers Due to Coronavirus Pandemic

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has temporarily suspended sales of its novel weight loss treatment to new patients at its existing retail treatment centers in San Diego and Orange County, California as a precaution against the spread of the coronavirus (COVID-19). The retail treatment centers will continue to fully treat and care for patients already in treatment with the Obalon Balloon System, and non-essential personnel will work remotely. “The safety, health and well-being of our patients, employees and providers remain our highest priority, therefore we are taking these steps to mitigate the impact of COVID-19 at Obalon retail facilities,” said Bill Plovanic, President and Chief Executive Officer of Obalon.

  • Thomson Reuters StreetEvents

    Edited Transcript of OBLN earnings conference call or presentation 27-Feb-20 1:30pm GMT

    Q4 2019 Obalon Therapeutics Inc Earnings Call

  • GlobeNewswire

    Obalon Announces Fourth Quarter and Full Year 2019 Financial Results

    SAN DIEGO, Feb. 27, 2020 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable,.

  • GlobeNewswire

    Obalon Announces Opening of Second Retail Treatment Center in Orange County, CA

    Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has opened its second Company-managed retail treatment center. “We are excited to have opened the second Company-managed Obalon Center for Weight Loss™, further developing our strategy to build a standardized, repeatable business using a Company-owned or managed retail treatment center model,” said Bill Plovanic, President and Chief Executive Officer of Obalon.

  • GlobeNewswire

    Obalon Schedules Fourth Quarter and Year-End 2019 Financial Results Conference Call for February 27, 2020 at 8:30 a.m. Eastern Time

    SAN DIEGO, Feb. 13, 2020 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Enters into New Stock Purchase Agreement with Lincoln Park Capital Fund

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a new common stock purchase agreement and registration rights agreement (together, the “Agreements”) with Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor, for up to $15 million. The new Agreements replace existing agreements between the Company and LPC. Under the terms of the Agreements and following the filing and effectiveness of a registration statement, Obalon will have the right at its sole discretion to sell to LPC up to $15 million worth of shares over a 36-month period, subject to various limitations including those under the NASDAQ listing rules.

  • Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is OBALON THERPTCS (OBLN) Stock Outpacing Its Medical Peers This Year?

    Is (OBLN) Outperforming Other Medical Stocks This Year?

  • Have Insiders Been Buying Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?
    Simply Wall St.

    Have Insiders Been Buying Obalon Therapeutics, Inc. (NASDAQ:OBLN) Shares?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Obalon Enters into a Distribution Agreement for Qatar

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces that it has entered into a one-year agreement with Al Danah Medical Company (“Al Danah”) for distribution of the Obalon Navigation Balloon System in Qatar. Obalon has terminated its agreement with Bader Sultan and Bros. Company for distribution of its prior-generation balloons, which was set to expire on December 31, 2019.

  • Thomson Reuters StreetEvents

    Edited Transcript of OBLN earnings conference call or presentation 8-Nov-19 2:00pm GMT

    Q3 2019 Obalon Therapeutics Inc Earnings Call

  • GlobeNewswire

    Obalon To Present at Two Upcoming Institutional Investor Conferences

    SAN DIEGO, Nov. 14, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company focused on commercializing the Obalon Balloon System, the first and.

  • Could Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Obalon Therapeutics, Inc.'s (NASDAQ:OBLN) Investor Composition Influence The Stock Price?

    The big shareholder groups in Obalon Therapeutics, Inc. (NASDAQ:OBLN) have power over the company. Generally speaking...

  • OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates
    Zacks

    OBALON THERPTCS (OBLN) Reports Q3 Loss, Misses Revenue Estimates

    OBALON THERPTCS (OBLN) delivered earnings and revenue surprises of 82.57% and -84.86%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Obalon Announces Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 08, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • GlobeNewswire

    Obalon Announces Clinical Data Set to be Featured During the 36th ASMBS Annual Meeting at Obesity Week 2019

    SAN DIEGO, Nov. 05, 2019 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks

    OBALON THERPTCS (OBLN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Obalon Schedules Third Quarter 2019 Financial Results Conference Call for November 8, 2019 at 9:00 a.m. Eastern Time

    SAN DIEGO, Oct. 31, 2019 -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

  • Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know
    Zacks

    Will OBALON THERPTCS (OBLN) Report Negative Q3 Earnings? What You Should Know

    OBALON THERPTCS (OBLN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Obalon Appoints William J. Plovanic as Chief Executive Officer and Nooshin Hussainy as Chief Financial Officer

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a San Diego-based weight loss solutions company focused on commercializing the Obalon Balloon System, the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for weight loss, announces that William J. Plovanic has been promoted to President and Chief Executive Officer, from his prior position of President and Chief Financial Officer. In conjunction with this change, Nooshin Hussainy, previously Vice President of Finance, has been promoted to the position of Chief Financial Officer. “In his prior role as President and CFO, Bill was instrumental in guiding the Company through its transition, galvanizing a new strategy to leverage our proprietary gastric-balloon weight loss system, and recapitalizing the business to fund the go-forward plan,” said Andy Rasdal, Executive Chairman of the Board of Directors at Obalon.

  • GlobeNewswire

    Obalon Announces First Patient Treatments at its First Company-Owned Center for Weight Loss

    Obalon Therapeutics, Inc. (NASDAQ:OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intra-gastric balloon for non-surgical weight loss, announces it has treated the first patients at its Company-owned weight loss treatment center, the Obalon Center for Weight Loss, in San Diego, California. The Obalon Center for Weight Loss is a medical facility staffed with physicians specializing in weight loss, nutritional counselors to help patients change their eating habits for sustainable weight loss, and other staff to help provide safe and effective treatment with the Obalon Balloon System.